Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Pyramidion Technology Group, Inc. (PYTG) Plans to Enter CBD or Cannabidiol Market Which Forbes Estimates $2.1 to $3 Billion by 2020

Pyramidion Technology Group,Inc
Posted on: 02 Aug 18
Pyramidion Technology Group, Inc. (PYTG) Plans to Enter CBD or Cannabidiol Market Which Forbes Estimates $2.1 to $3 Billion by 2020 Company In Process Of Negotiating An Acquisition Of A Company That Markets Cannabidiol (CBD) Based Products

PR Newswire

WESTON, Florida, August 2, 2018

WESTON, Florida, August 2, 2018 /PRNewswire/ --

Pyramidion Technology Group, Inc. ("PYTG", or the "Company") (OTC PINK: PYTG), today announced that it plans to enter the CBD based products market and is looking to acquire a company that markets premium quality independently certified all-natural wellness products, as part of its plan to become a global cannabis industry leader dedicated to the research, development, and the multi-national wholesale and retail distribution of premium proprietary products, "The CBD or cannabidiol market could grow 700% by 2020 as more people turn to these products for health improvements."https://www.facebook.com/forbes/posts/10154841517757509

FORBES has said that the CBD market could grow to $2.1 to $3 Billion by 2020. The article also went on to describe CBD based products as: "Cannabidiol (CBD) is the part of the cannabis plant that doesn't get you "high" like the THC side of the plant. It is typically used for health reasons instead of for recreational purposes.

https://www.forbes.com/sites/debraborchardt/2016/12/12/the-cannabis-market-that-could-grow-700-by-2020/#66305684be1e

The Hemp Business Journal  estimated that the CBD market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources. That's a 700% increase from 2016. In 2015, the market for consumer sales of hemp-derived CBD products was $90 million, plus another $112 million in marijuana-derived CBD products which were sold through dispensaries - bringing a total CBD market to $202 million last year.

Carlos Hurtado, CEO and President of the Company, said, "We want to be up front about the wave in this rapidly growing Cannabidiol (CBD) market arena and we believe that's just what this potential acquisition does for the Company and our loyal shareholders."

Mr. Hurtado continued: "Our target company, sources directly from third party manufacturers, and already has a significant customer/reseller base buying CBD products.

The Company believes that the revenues to be generated by this new acquisition will have a significant positive impact to the Company's bottom line this fiscal year."

About Pyramidion Technology Group, Inc.    

Pyramidion Technology Group, Inc. ("PYTG" or the "Company") is best described as a business incubator. The purpose of our business model is to leverage equity, to acquire, merge and or joint venture with early stage companies in emerging sectors, to facilitate growth and cash flow utilizing a diverse distribution methods.

Our intention is to develop and acquire fast growing companies in up-trending industries and positioning technology for economic growth. This platform will combine natural relationships, marketing synergies and distribution methods that enable combined companies to provide a wide variety of unique and complete solutions, services and necessities to consumers. We believe our overall business model could effectively create a company of unlimited opportunities for our growing shareholder base.

For more information on PYTG, please visit the Company's website at https://www.pytgcorp.com.com/.

To be added to the Company investor email list, please email info@pytgcorp.com with PYTG in the subject line.

FORWARD-LOOKING STATEMENTS 

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance

on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at https://www.otcmarkets.com/stock/PYTG/filings.

Contact:
Investor Contact: info@pytgcorp.com
Phone: +1-954-329-2205


SOURCE Pyramidion Technology Group, Inc

PR Newswire
www.prnewswire.com

Last updated on: 02/08/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.